优化对激素敏感的转移性前列腺癌患者的三联疗法。

A Borque-Fernando, D A Pérez-Fentes, M Rodrigo-Aliaga, J Puente-Vázquez, A Gómez-Iturriaga, M Unda, M A Calleja-Hernández, J M Cózar-Olmo, J L Álvarez-Ossorio
{"title":"优化对激素敏感的转移性前列腺癌患者的三联疗法。","authors":"A Borque-Fernando, D A Pérez-Fentes, M Rodrigo-Aliaga, J Puente-Vázquez, A Gómez-Iturriaga, M Unda, M A Calleja-Hernández, J M Cózar-Olmo, J L Álvarez-Ossorio","doi":"10.1016/j.acuroe.2024.10.005","DOIUrl":null,"url":null,"abstract":"<p><p>Triple therapy with docetaxel, androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) has demonstrated survival benefits in patients with metastatic hormone-sensitive prostate cancer (mHSPC), especially in those with high-risk disease. However, once the use of ADT and docetaxel is established, guidelines do not clearly specify which ARPI is most appropriate. In this work, a literature review to identify phase III clinical trials, systematic reviews, meta-analyses, and clinical practice guidelines on triple therapy in mHSPC was carried out. Evidence and recommendations were qualitatively reviewed to provide guidelines on the most suitable ARPI based on patient risk, disease volume, and nature of metastases (synchronous or metachronous). This review aims to update the previously published consensus on the optimal pharmacological treatment for mHSPC and to expose the opinions of hospital pharmacy, urology and medical and radiation oncology experts.</p>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Optimizing triple therapy in patients with metastatic hormone-sensitive prostate cancer.\",\"authors\":\"A Borque-Fernando, D A Pérez-Fentes, M Rodrigo-Aliaga, J Puente-Vázquez, A Gómez-Iturriaga, M Unda, M A Calleja-Hernández, J M Cózar-Olmo, J L Álvarez-Ossorio\",\"doi\":\"10.1016/j.acuroe.2024.10.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Triple therapy with docetaxel, androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) has demonstrated survival benefits in patients with metastatic hormone-sensitive prostate cancer (mHSPC), especially in those with high-risk disease. However, once the use of ADT and docetaxel is established, guidelines do not clearly specify which ARPI is most appropriate. In this work, a literature review to identify phase III clinical trials, systematic reviews, meta-analyses, and clinical practice guidelines on triple therapy in mHSPC was carried out. Evidence and recommendations were qualitatively reviewed to provide guidelines on the most suitable ARPI based on patient risk, disease volume, and nature of metastases (synchronous or metachronous). This review aims to update the previously published consensus on the optimal pharmacological treatment for mHSPC and to expose the opinions of hospital pharmacy, urology and medical and radiation oncology experts.</p>\",\"PeriodicalId\":94291,\"journal\":{\"name\":\"Actas urologicas espanolas\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Actas urologicas espanolas\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.acuroe.2024.10.005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Actas urologicas espanolas","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.acuroe.2024.10.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

多西他赛、雄激素剥夺疗法(ADT)和雄激素受体通路抑制剂(ARPI)三联疗法已证明对转移性激素敏感性前列腺癌(mHSPC)患者,尤其是高危患者的生存有好处。然而,一旦确定使用 ADT 和多西他赛,指南并未明确规定哪种 ARPI 最为合适。在这项工作中,我们进行了一项文献综述,以确定有关 mHSPC 三联疗法的 III 期临床试验、系统综述、荟萃分析和临床实践指南。对证据和建议进行了定性审查,以根据患者风险、疾病体积和转移性质(同步或同步)提供最合适的 ARPI 指南。本综述旨在更新之前发表的关于 mHSPC 最佳药物治疗的共识,并阐述医院药剂学、泌尿科、肿瘤内科和放射科专家的意见。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Optimizing triple therapy in patients with metastatic hormone-sensitive prostate cancer.

Triple therapy with docetaxel, androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) has demonstrated survival benefits in patients with metastatic hormone-sensitive prostate cancer (mHSPC), especially in those with high-risk disease. However, once the use of ADT and docetaxel is established, guidelines do not clearly specify which ARPI is most appropriate. In this work, a literature review to identify phase III clinical trials, systematic reviews, meta-analyses, and clinical practice guidelines on triple therapy in mHSPC was carried out. Evidence and recommendations were qualitatively reviewed to provide guidelines on the most suitable ARPI based on patient risk, disease volume, and nature of metastases (synchronous or metachronous). This review aims to update the previously published consensus on the optimal pharmacological treatment for mHSPC and to expose the opinions of hospital pharmacy, urology and medical and radiation oncology experts.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信